Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates AAPG Bearish with a Setup Score of 25, net conviction 29, actionability 22. How the Setup Score works →
| Total Setup Score | 25 |
|---|---|
| Directional Bias | Bearish |
| Net Conviction | 29 |
| Actionability | 22 (in range) |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; A… Read full Trend Edge analysis →
| Current Price | $17.34 |
|---|---|
| Market Cap | $1.60B |
| Float | 55.7M |
| Shares Outstanding | 93.3M |
| Price/Sales (TTM) | 2.78 |
| vs. Analyst Target | +174.3% to analyst PT |
| Profit Margin | -216.47% |
| Operating Margin (TTM) | -193.35% |
| Revenue (TTM) | $574M |
| Dividend Rate | None |
| Analyst Target Price | $47.56 (2 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $12.4M | -$678M | $10.5M | -$652M |
| 2021 | $27.9M | -$782M | $24.6M | -$798M |
| 2022 | $210M | -$883M | $188M | -$787M |
| 2023 | $222M | -$926M | $191M | -$744M |
| 2024 | $981M | -$405M | $952M | -$238M |
| 2025 | $558M | -$1.21B | $427M | -$1.10B |
| Quarter | Revenue | Net Income |
|---|---|---|
| Mar 2025 | $157M | -$568M |
| Jun 2025 | $234M | -$591M |
| Dec 2025 | $334M | -$640M |
| Mar 2026 | $334M | -$640M |
| Institutional Ownership | 0.1% |
|---|---|
| Short Float | 0.0% |
| % of All Funds Holding | 0.07% |
| Number of Funds Holding | 6 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $20.88 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $27.14 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $26.36 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $22.80 | resistance | 1.37x | 0 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.22% | 0.16% | 50.00% | 2.24% | -1.70% |
| 1 Day | 0.42% | 1.29% | 75.00% | 3.96% | -4.84% |
| 1 Week | 10.65% | 9.23% | 50.00% | 35.10% | -10.96% |
| 2 Weeks | 9.66% | 8.72% | 75.00% | 35.15% | -13.95% |
| 1 Month | -0.32% | -6.95% | 50.00% | 34.19% | -21.56% |
Next earnings: August 19, 2026 (64 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 0.1%
Founder-led management: Dajun Yang (Co-Founder, Chairman & CEO), Shaomeng Wang (Co-Founder, Chief Scientific Advisor & Non-Executive Director)
Full insider transaction history and smart buy/sell sentiment summary available on Trend Edge.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Ascentage Pharma Group International (AAPG) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for AAPG on Trend Edge →